go to topGene Engineering Division > Depositors List >
Ryohei Katayama's web page in English / in Japanese
Learn more about their research in Researchmap
| Catalog # | Name of clone | Running title | Publication |
| RDB15496 | pENTER-EGFR C797S/T790M/L858R | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15495 | pENTER-EGFR C797S/L858R | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15494 | pENTER-EGFR T790M/L858R | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15493 | pENTER-EGFR L858R | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15492 | pENTER-EGFR C797S/T790M/del19 | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15491 | pENTER-EGFR C797S/del19 | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15490 | pENTER-EGFR T790M/del19 | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15489 | pENTER-EGFR Del19 | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-activating mutation. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
| RDB15488 | pENTER-EGFR wild-type | Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), wild type. | Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [PubMed] [Article] [RRC of NBRP] (original) |
2026.03.30
depxxxx_html_4_250330.pl